广东因微于2015年由中国顶级生物物理机构的专业科学家团队创立。广东因微主要从事生物芯片研发、高通量测序、大数据云计算分析及个性化医疗谘询服务。近年来，广东因微在肿瘤、心脑血管疾病、糖尿病、神经系统等多种疾病检测生物芯片研发方面取得巨大成功。董事认为，收购事项可进一步提升集团在生物科技行业的科研实力及创新能力，以及丰富集团的产品线，并为集团现有业务带来协同效益。预计实现广东因微的生物芯片产品销售后可落实本公司的投资回报及改善集团的财务表现，旨在实现股东回报最大化。Sino-life group (08296.HK) announced on July 29th that the company and Zhongke Xunda (a wholly-owned subsidiary of the company) have signed an equity transfer agreement with Nanyue Assets on July 29th, 2024. According to the equity transfer agreement, the company and Zhongke Xunda conditionally agreed to purchase Nanyue Assets' equity in Guangdong Yinwei (equivalent to approximately 19.46% equity in Guangdong Yinwei) for a maximum consideration of RMB 10.8 million, and will pay through issuing convertible bonds to Nanyue Assets or its designated person according to the special authorization. After the equity transfer agreement is completed, Zhongke Xunda will hold approximately 19.46% equity in Guangdong Yinwei.
Guangdong Yinwei mainly engages in the development of biochips, high-throughput sequencing, big data cloud computing analysis, and personalized medical consultation services. It provides biochips for biomedical research and clinical diagnosis for medical institutions, physical examination institutions, scientific research institutions, pharmaceutical companies, and other clients, as well as related services.
The group has been actively seeking to diversify its sources of revenue to enhance shareholder returns. The group has formed a business structure with traditional funeral services and emerging biotechnology as the main business. The group has been involved in the biotechnology business since early 2019.
Guangdong Yinwei was founded in 2015 by a team of professional scientists from China's top biophysical institutions. Guangdong Yinwei mainly engages in the development of biochips, high-throughput sequencing, big data cloud computing analysis, and personalized medical consultation services. In recent years, Guangdong Yinwei has achieved great success in the development of biochips for the detection of various diseases, such as tumors, cardiovascular diseases, diabetes, and the nervous system. The directors believe that the acquisition can further enhance the group's research strength and innovation capabilities in the biotechnology industry, and enrich the group's product line, bringing synergy benefits to the existing business of the group. It is expected to achieve investment returns and improve the financial performance of the group after the sale of Guangdong Yinwei's biochip products, aimed at maximizing shareholder returns.
